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Background Alzheimer’s disease (AD) biomarkers are important for early diagnosis in 
clinical routine and trials. Three core AD cerebrospinal fluid (CSF) biomarkers (Aβ42, T-tau, 
and P-tau) have been evaluated in numerous studies and there are several emerging AD 
markers. However, there is no comprehensive meta-analysis of their diagnostic performance.  
Methods We screened PubMed and Web of Science for articles on CSF and blood 
biomarkers reflecting neurodegeneration (T-tau, NFL, NSE, VLP-1, and HFABP), amyloid 
precursor protein (APP) metabolism (Aβ42, Aβ40, Aβ38, sAPPα, and sAPPβ), tangle 
pathology (P-tau), blood-brain-barrier function (albumin ratio) and glial activation (YKL-40, 
MCP-1, and GFAP). Based on inclusion criteria, 231 of 13,319 screened articles were 
included. Biomarker performance was rated on fold change between AD and controls and 
between mild cognitive impairment (MCI) who later converted to AD (MCI-AD) and stable 
MCI who had at least a follow-up time of two years.  
Findings Core biomarkers differentiated AD from controls with excellent performance; CSF 
T-tau (2·54, CI 2·44-2·64, p<0·0001, 152 studies), P-tau (1·88, CI 1·79-1·97, p<0·0001, 91 
studies), and Aβ42 (0·56, CI 0·55-0·58, p<0·0001, 131 studies). Differentiation between 
MCI-AD and stable MCI was also strong (0·66-1·81). Furthermore, CSF NFL (2·35, 95% CI 
1·90-2·91, p<0·0001) and plasma T-tau (1·95, 95% CI 1·12-3·38, p=0·02) had large effect 
sizes, while CSF NSE, VLP-1, HFABP, and YKL-40 were more moderate (1·28-1·47). 
Remaining biomarkers had marginal effect sizes or were non-significant.  
Interpretation Core CSF AD biomarkers and NFL, as well as plasma T-tau, are strongly 
associated with AD. Emerging biomarkers CSF NSE, VLP-1, HFABP, and YKL-40 are 
moderately associated with AD, while plasma Aβ42 and Aβ40 are not. 
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Introduction 
Alzheimer’s disease (AD) is the most common neurodegenerative disease. Its 
neuropathological hallmarks are amyloid β (Aβ)-containing plaques, and tau-containing 
neurofibrillary tangles.1 It is generally acknowledged that several drug candidates, most 
targeting Aβ, have failed in large, multi-centre clinical trials in part because a large proportion 
of clinically diagnosed patients show no evidence of amyloid pathology on PET scans, and 
thus do not have AD.2 This diminishes the possibility of identifying a clinical benefit of the 
tested drug and points to the need for validated biomarkers in drug development and clinical 
practice. 
Over the past 25 years, three core AD cerebrospinal fluid (CSF) biomarkers have been 
identified and tested in hundreds of studies. These are the 42 amino acid form of Aβ (Aβ42) 
with low levels due to cortical amyloid deposition, total tau (T-tau) with high levels due to 
cortical neuronal loss,3-6 and phosphorylated tau (P-tau) with high levels reflecting cortical 
tangle formation.7,8 High diagnostic accuracy of these biomarkers has been demonstrated for 
AD, with sensitivity and specificity reaching 85-90%, and also for prodromal AD in the mild 
cognitive impairment stage of the disease (MCI-AD).9 Biomarkers have also been 
incorporated in modern diagnostic criteria. 10 However, individual studies vary greatly and no 
comprehensive meta-analysis has evaluated their diagnostic performance. Nor has emerging 
biomarkers reflecting neurodegeneration, glial cell activation, and amyloid precursor protein 
(APP) metabolism, which show promise as diagnostic tools,11 yet been meta-analyzed. 
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In the present paper, we have examined the literature on 15 biomarkers in both CSF and 
blood, covering core AD biomarkers as well as other markers of neurodegeneration, glial and 
blood-brain-barrier (BBB) function, and APP metabolism, to determine which ones separate 
AD from controls and MCI-AD from stable MCI.  
Methods 
Search strategy and selection criteria 
We did this study according to the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement.12 We screened articles published in PubMed and Web 
of Science between 1984 (when the first diagnostic criteria were published)13 and June 30th, 
2014, which reported data on biomarkers of neurodegeneration (T-tau,3-6 neurofilament light 
protein (NFL),14 neuron-specific enolase (NSE),15 visinin-like protein 1 (VLP-1),16 and heart 
fatty acid binding protein (HFABP)17), APP metabolism (Aβ42, Aβ40, Aβ38, α and β cleaved 
soluble amyloid precursor protein (sAPPα, and sAPPβ)), tangle pathology (P-tau),7,8 BBB 
function (CSF/serum albumin ratio) and glial activation (YKL-40,28,29 monocyte chemotactic 
protein 1 (MCP-1),18 and glial fibrillary acidic protein (GFAP)19) in CSF and blood (serum or 
plasma) in AD vs. controls or MCI-AD vs. stable MCI (Table 1). It is important to note that 
only a few of these markers have been validated against neuropathology and that the precise 
process their CSF levels reflect is tentative until such studies have been performed.20 For 
detailed search terms, see Supplemental Methods. The review protocol can be found at 
http://www.alzforum.org/alzbiomarker/about-alzbiomarker/methods. Additional records were 
identified through reference lists of included articles (Figure 1). Data was independently 
extracted by ten authors. Plasma and serum analyses for each biomarker were meta-analyzed 
together. Data were curated from cross-sectional cohort studies as well as from baseline 
measurements in longitudinal studies with clinical follow-up. All entered data was checked by 
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two researchers. Stable MCI was defined as having a follow-up of at least 2 years without 
meeting dementia diagnosis. MCI-AD was defined as baseline MCI with progression to AD 
dementia at follow-up. Controls included cognitively normal volunteers (spouses or 
volunteers recruited by other means from the population) or individuals who were sampled 
when admitted to hospital, e.g., for a surgical procedure that required spinal anaesthesia, and 
who proved cognitively normal when tested.  
Exclusion criteria for entire studies or individual cohorts were: 1) Articles not written in 
English. 2) Studies not containing AD and a control cohort, or MCI-AD and a stable MCI 
cohort. 3) Cohorts with fewer than ten individuals. 4) Data reported in a format other than 
mean±SD or mean±SEM (study authors were contacted and asked to supply this information). 
5) Biomarker data from urine, saliva, or cellular blood fractions. 6) Studies using non-
quantitative methods, e.g., explorative proteomics or western blot. 7) Cohorts lacking 
diagnostic criteria for AD or MCI, or cohorts representing a mix of diagnoses. 8) Cohorts of 
stable MCI with less than two years follow-up. 9) Cohorts of individuals younger than 18 
years of age. 10) Studies lacking appropriately referenced methods, with the exception of 
CSF/serum albumin ratio which we accepted as a well-established routine analysis. 11) 
Previously published data. This also includes large initiatives such as ADNI where the same 
biomarkers are listed in many articles but only measured once and therefore only the first 
article where a biomarker is presented was included in this study. Finally, for longitudinal 
cohorts with several publications on the same baseline data, we included the publication that 
had the longest follow-up. 12) Control cohorts containing subjects with inflammatory, 
neurological, or psychiatric diagnoses that may affect CSF biomarker levels.  
Här måste vi beskriva QUADAS (inklusive ta med QUADAS-referenserna som finns i SBU-
dokumentet), ungefär så som du skriver i referee-svaret. Resultatet av QUADAS (hur många 
som hade high och medium quality) skall stå i Results första paragraf.  
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Statistical analysis 
There is a large variation in how different laboratories establish cut-points. Some use 
historical in house data, some establish optimal cut-off points within the same cohort or from 
an external cohort and some use reference limits established on healthy subjects; these are just 
some of the approaches used. Furthermore, there is significant variability in biomarker levels 
between laboratories and assays.21 The application of fold change reduces these problems. 
Hence, we performed meta-analyses using the AD/control ratios and the MCI-AD/stable MCI 
ratios; each specific ratio was generated within a single study. In studies with more than one 
control cohort, only the most cognitively normal (i.e., healthy controls over hospital controls) 
and age appropriate cohort was used. In studies with more than one AD cohort, all AD 
cohorts were included and divided by the control group to generate multiple ratios per study. 
In cohorts where a biomarker was analyzed with more than one assay we included only one of 
them and chose a commercial assay over an in-house assay. Standard error of the ratio of the 
mean values was calculated using the delta method.22,23 Random effects meta-analysis using 
the method of DerSimonian and Laird with the estimate of heterogeneity taken from the 
inverse-variance fixed-effect model was applied in Stata 13.1 (metan command sbe24_3).24 P-
values ≤0·05 were considered significant. Publication bias was assessed using funnel plots. 
The study protocol is listed on http://www.alzforum.org/alzbiomarker/about-
alzbiomarker/methods. 
 
Role of the funding source 
Funders of the study had no role in study design, data collection, analysis, interpretation, or 
writing of the report with the exception of the Biomedical Research Forum LLC, employees 
of which were involved in the development of the AlzBiomarker database, revised the 
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manuscript, and are co-authors here. All authors had full access to all the data in the study and 
had final responsibility for the decision to submit for publication. 
Results 
The initial screening identified 13,319 articles, 675 full-text articles were assessed for 
eligibility and 231 articles were included (Figure 1). 
Core biomarkers 
We found most eligible studies for T-tau. A total of 165 AD and 154 control cohorts in 152 
studies had data on CSF T-tau, comprising 11,341 AD patients and 7,086 controls. All studies 
had an AD/control ratio above one, with an average of 2·54 (95% CI 2·44-2·64, p<0·0001; 
Fig 2A). For CSF P-tau, we combined data from studies using single or multiple epitopes for 
detection. In 91 studies, a total of 7,498 AD patients from 98 cohorts and 5,126 controls from 
91 cohorts were included. As was the case for T-tau, all AD/control P-tau ratios were above 
one, with an average of 1·88 (95% CI 1·79-1·97, p<0·0001; Fig 2B). In the meta-analysis of 
Aβ42, we included studies using assays covering the 1-42 as well as the x-42 epitopes. A total 
of 143 AD cohorts and 135 control cohorts in 131 studies with 9,949 AD patients and 6,841 
controls were included. The CSF Aβ42 ratio between AD and controls was below one in all 
comparisons but one, with an average of 0·56 (95% CI 0·55-0·58, p<0·0001; Fig 2C). The 
funnel plots suggested publication bias for all three core biomarkers. 
Markers of neurodegeneration 
Data on NFL in CSF were available from nine AD and eight control cohorts comprising 245 
AD patients and 292 controls (average ratio 2·35, 95% CI 1·90-2·91, p<0·0001; Fig 3A), and 
on NSE from seven cohorts including 258 AD patients and 160 controls (average ratio 1·47, 
95% CI 1·08-2·00, p=0·01; Fig 3B). VLP-1 was analyzed in four AD (n=252) and control 
(n=486) cohorts (average ratio 1·46, 95% CI 1·31-1·62, p<0·0001; Fig 3C) and HFABP in 
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five AD (n=285) and control (n=297) cohorts (average ratio 1·39, 95% CI 1·24-1·57, 
p<0·0001; Fig 3D). The funnel plots suggested no publication bias for markers of 
neurodegeneration. 
Glial markers  
The microglial and astrocyte marker YKL-40 was analyzed in six AD and five control cohorts 
with 298 and 330 subjects, respectively. It was significantly elevated with an average ratio of 
1·28 (95% CI 1·23-1·35, p<0·0001; Fig 3E). In contrast, the astrocyte marker GFAP did not 
differ between AD and controls (average ratio 1·12, 95% CI 0·58-2·15, p=0·74, from two AD 
and control cohorts of 59 and 39 subjects respectively; Fig 3F). The microglial marker MCP-1 
had a small but significant effect size in three cohorts of AD and controls with 59 subjects in 
each group (average ratio 1·12 95% CI 1·06-1·18, p<0·0001; Fig 3G). The funnel plots 
suggested no publication bias for glial markers. 
Marker of BBB 
We analyzed CSF/serum albumin ratio in AD (20 cohorts, n=854) vs. controls (16 cohorts, 
n=441). The ratio was significantly elevated but the effect size was small (average ratio 1·10, 
95% CI 1·01-1·20, p=0·04; Fig 3H). The funnel plots suggested no publication bias for the 
marker of BBB. 
Markers of APP metabolism  
APP cleavage generates a host of quantifiable products besides Aβ42. Aβ40 was the second-
most studied amyloid marker. It was analyzed in 25 AD and 24 control cohorts with 1,079 
and 784 subjects, respectively. The average effect size was significant but minor 0·94 (95% 
CI 0·90-0·99, p=0·02; Supplementary fig 1A). Aβ38 was analyzed in eight studies with 251 
AD patients and 195 controls (average ratio 0·99, 95% CI 0·88-1·12, p=0·89, Supplementary 
fig 1B). Both sAPPα and sAPPβ are cleavage products from APP. Neither sAPPα (average 
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ratio 1·03, 95% CI 0·93-1·14, p=0·55), from nine AD (n=572) and control (n=415) cohorts 
(Supplementary fig 1C), nor sAPPβ (average ratio 1·02, 95% CI 0·95-1·09, p=0·61), from ten 
cohorts of 631 AD and 439 controls (Supplementary fig 1D) differed between AD patients 
and controls. The funnel plots suggested no publication bias for markers of APP metabolism. 
Plasma and serum biomarkers  
In contrast to the significantly lower CSF levels of Aβ42 in AD compared with controls, the 
average ratio of plasma Aβ42 between AD and controls was non-significant and close to one 
in the analysis of 22 AD and 20 control cohorts comprising 1,872 AD and 3,855 controls 
(average ratio 1·04, 95% CI 0·96-1·12, p=0·32; Supplementary fig 2A). Besides Aβ42, the 
plasma and serum literature had sufficient data for meta-analysis only for Aβ40, T-tau, YKL-
40, NSE, MCP-1, and HFABP. Aβ40 was not significantly different between AD and controls 
(average ratio 1·04, 95% CI 0·98-1·11, p=0·17) in 21 AD (n=1,661) and 19 control cohorts 
(n=3,668; Supplementary fig 2B). Data from six AD and five control cohorts on T-tau, 
comprising 271 AD and 394 controls, showed a large effect size (average ratio 1·95, 95% CI 
1·12-3·38, p=0·02; Supplementary fig 2C). There were no differences between AD and 
controls for NSE (average ratio 1·00, 95% CI 0·86-1·17, p=0·99) in three AD (n=102) and 
control cohorts (n=97; Supplementary fig 2D) or for HFABP (average ratio 1·05, 95% CI 
0·83-1·33, p=0·69) in two AD (n=55) and control (n=74) cohorts (Supplementary fig 2E). For 
YKL-40, the effect size was large but just not significant in three AD and two control cohorts 
with 155 AD and 233 controls, respectively (average ratio 1·95, 95% CI 0·99-3·84, p=0·053; 
Supplementary fig 2F). However, there was no difference between AD and controls for MCP-
1 (average ratio 1·00, 95% CI 0·89-1·13, p=0·99) in six AD (n=540) and control (n=344) 
cohorts (Supplementary fig 2G). The funnel plots suggested no publication bias for plasma 
and serum biomarkers. 
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Biomarkers in MCI 
All 12 eligible comparisons of CSF T-tau between MCI-AD (n=307) and stable MCI (n=570) 
had a ratio above one, with an average of 1·76 (95% CI 1·64-1·89, p<0·0001; Supplementary 
fig 3A). Likewise, all nine comparisons of CSF P-tau between MCI-AD (n=251) and stable 
MCI (n=501) had a ratio above one, with an average of 1·72 (95% CI 1·46-2·02, p<0·0001; 
Supplementary fig 3B). CSF Aβ42 concentrations were also significantly lower in MCI-AD 
(12 cohorts, n=352) compared with stable MCI (12 cohorts, n=610), albeit with a smaller 
effect size than between AD and controls (average ratio 0·67, 95% CI 0·63-0·73, p<0·0001; 
Supplementary fig 3C). In contrast, CSF Aβ40 was not significant between three cohorts each 
with 152 MCI-AD and 189 stable MCI patients (average ratio 0·98, 95% CI 0·90-1·07, 
p=0·71; Supplementary fig 3D). Neither was the average ratio of plasma Aβ42 from three 
MCI-AD (n=308) and stable MCI (n=379) cohorts (average ratio 0·81, 95% CI 0·53-1·24, 
p=0·32; Supplementary fig 3E). However, the average ratio of plasma Aβ40 was significantly 
different between three MCI-AD (n=308) and stable MCI (n=379) cohorts, but the effect size 
was negligible (average ratio 1·07, 95% CI 1·03-1·10, p=0·0002; Supplementary fig 3F). 
Neither sAPPα nor sAPPβ was significantly changed in CSF between MCI-AD and stable 
MCI; sAPPα from three MCI-AD (n=118) and stable MCI (n=169) cohorts (average ratio 
1·09 95% CI 0·96-1·25, p=0·20; Supplementary fig 3G) and sAPPβ from three MCI-AD 
(n=118) and stable MCI (n=169) cohorts (average ratio 1·06, 95% CI 0·87-1·28, p=0·59; 
Supplementary fig 3H). The funnel plots suggested no publication bias for biomarkers in 
MCI. 
Biomarker performance 
Head-to-head biomarker performance is shown in Figure 4A-B. 
Discussion 
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Our study provides by far the most comprehensive meta-analysis of the rapidly growing 
biomarker literature in AD. It shows unequivocally that AD is associated with lower CSF 
levels of Aβ42 and higher CSF levels of T-tau and P-tau compared with controls. 
Furthermore, AD is associated with increased CSF levels of NFL, NSE, VLP-1, HFABP, 
YKL-40, and increased plasma levels of T-tau. 
Fluid biomarker measurement in AD is marked by variability between laboratories and 
batches of commercial assays, which are research-grade but not clinically certified.21 This 
precluded a traditional meta-analysis based on existing cut-off levels. Furthermore, our 
analysis included a multitude of in-house assays, some of which used different epitopes in the 
same molecule, particularly for Aβ42 and P-tau. Some Aβ42 assays use antibodies targeting 
the first and last amino acids, i.e. Aβ1-42, or a mid-domain epitope in combination with an 
end-specific antibody, designated Aβx-42. Tau is phosphorylated at multiple sites, but most 
assays only detect the phosphorylation of one specific amino acid. To circumvent this 
methodological variability, we used ratios of AD/control and MCI-AD/stable MCI biomarker 
levels for meta-analysis and combined the analyses of relevant forms of a specific protein into 
one. Neither for Aβ42 nor for P-tau did the literature indicate superiority of a particular 
epitope. In our meta-analysis, different assays using different antibody combinations against 
Aβ42 generated similar results (Supplement). For P-tau, the other epitopes besides P-tau181 
were analyzed in too few studies to evaluate differences in performance.  
The picture was unanimous for T-tau and P-tau; all studies had an AD/control ratio above 
one. The results were also remarkably consistent for Aβ42 in CSF, with 139 studies finding 
an AD/control ratio below one, with just one outlier, Jensen et al,25 finding a ratio above one. 
A plausible explanation for this anomaly is that the Aβ42 levels of the controls in their study 
were exceptionally low, only 40% of the levels in a simultaneously analyzed cohort with 
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depression. Normally, CSF Aβ42 levels are similar between controls and patients with 
depression.26  
The CSF signature of elevated T-tau and P-tau and reduced Aβ42 was also observed in MCI-
AD compared with stable MCI, although the effect was somewhat less pronounced. Most 
likely, some individuals categorized as stable MCI were in fact developing prodromal AD 
thereby diverging in their biomarker profile from healthy controls. This interpretation is 
supported by results showing that the drop in CSF Aβ42 levels precedes AD dementia by at 
least ten years.27-29 To minimize this problem, we excluded all mixed MCI cohorts and 
required that stable MCI cohorts had a follow-up period of at least two years with cognitive 
stability. Even so, this problem cannot be totally avoided since the only way to estimate early 
non-clinical signs of progression, except for very long follow-up or post-mortem 
examinations, is through the use of CSF or imaging markers of AD pathology, which would 
be a form of catch 22 if taken into account. It is also worth to note that clinical AD does not 
guarantee AD pathology and that normal cognition does not guarantee absence of AD 
pathology. However, this is an issue that we cannot solve in this study since we have to rely 
upon the clinical diagnostic criteria that were listed in the studies since only very few have 
autopsy confirmed diagnoses. 
Among the new or less studied CSF biomarkers, NFL showed a large effect size (2·35). NFL 
is the light protein of neurofilament and, with either the medium or the heavy counterpart, 
makes up neurofilament bundles that determine axonal caliber and conduction velocity.14 
Thus, our data indicate that axonal destruction is prominent in AD. Furthermore, NSE, VLP-
1, HFABP, and YKL-40 had a moderately large (1·28-1·47) and significant effect size 
between AD and controls. NSE is a neuron-enriched enzyme of the glycolytic pathway,15 
VLP-1 is a calcium-sensor protein found in the neuronal cytoplasm,16 HFABP is an 
intracellular fatty acid transport protein expressed in skeletal muscle heart and neurons,17 and 
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YKL-40 is a marker of activated microglia and astrocytes.30,31 None of these markers reflect 
the core pathology of AD; nevertheless, this meta-analysis suggests that they could be useful 
in clinical trials of anti-AD drugs as tau- and Aβ-independent measures of neurodegeneration 
and glial activation. In contrast, although CSF Aβ40 and MCP-1 and CSF/serum albumin 
ratio were statistically different between AD and controls, their small effect size precludes 
their use as diagnostic markers. Moreover, our meta-analysis suggests that sAPPα, sAPPβ, 
and Aβ38 are not useful in AD diagnostics.  
Acceptance of lumbar puncture by physicians varies from country to country, therefore 
plasma is considered a desirable matrix for AD biomarker analyses. When all studies were 
weighed in, we found no significant differences between Aβ markers in AD and controls, 
supporting the hypothesis that plasma Aβ levels reflect peripheral Aβ generation more than 
AD brain pathology. In contrast, plasma levels of T-tau were significantly associated with 
AD. Variation in the few available studies was large, therefore more data are needed to verify 
this association.  
Despite conducting exhaustive PubMed and the Web of Science searches, we might have 
missed some eligible studies. Some studies reported data in a format unsuitable for our 
analysis; for these studies we requested the missing data from the corresponding authors and 
most responded. All studies for T-tau and P-tau had a ratio above one and all but one a ratio 
below one for Aβ42 indicating that the results for these biomarkers are solid. However, there 
was publication bias for all three core biomarkers between AD and controls and therefore the 
results will have to be interpreted in the light of this. Furthermore, this indicates that the 
heterogeneity is small for the core biomarkers. In contrast, some heterogeneity can be 
observed in the forest plots for the other biomarkers in spite of the use of the fold change 
approach. Potential reasons for heterogeneity in the results of the less established biomarkers 
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include smaller studies and less established and validated assays compared with the core 
biomarkers, as well as less knowledge on potential confounding pre-analytical factors.   
To extract maximal knowledge from the abundance of fluid biomarker studies published in 
recent years, data must first be extracted, aggregated, and organized. Therefore, in 
conjunction with this manuscript, we have developed an open-access database containing the 
curated data and meta-analyses shown here. The AlzBiomarker database, which is hosted at 
www.alzforum.org, contains additional curated data, such as mean age of subjects, MMSE 
scores, and duration of disease. In addition, interactive visuals allow users to compare results, 
explore promising biomarkers, methods and assays, as well as to identify knowledge gaps.  
The database will be updated with new data and meta-analyses as additional studies are 
published. 
In conclusion, CSF Aβ42, T-tau, P-tau, and NFL are biomarkers that, at least on a group level, 
robustly separate AD patients from controls, while CSF NSE, VLP-1, HFABP, and YKL-40 
show more moderate differences. Importantly for earlier detection, CSF Aβ42, T-tau, and P-
tau also discriminate between MCI-AD and stable MCI. Plasma T-tau is the only blood 
biomarker that separates AD from controls; this finding needs verification in larger cohorts. 
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Table 1. Biomarkers analyzed where available in AD vs. CTRL and MCI-
AD vs. stable MCI in CSF, serum and plasma.  
Neurodegeneration 
T-tau NFL NSE VLP-1 HFABP 
APP metabolism 
Aβ42 Aβ40 Aβ38 sAPPα sAPPβ 
Tangle pathology 
P-tau     
Glial activation 
YKL-40 MCP-1 GFAP   
BBB function 




Figure 1: Study selection.  
 
Figure 2: AD/control ratios for CSF core biomarkers.  
CSF ratios of T-tau (A), P-tau (B) and Aβ42 (C) between AD and control groups. Individual 
AD/control ratios and their corresponding 95% CIs are indicated by filled squares. The size of 
the square indicates the weight of the study. All average ratios and their corresponding 95% 
21 
CIs are indicated by clear diamonds. The solid line indicates a ratio of one and the dotted 
indicates the average ratio.  
 
Figure 3: AD/control ratios for CSF markers of neurodegeneration, glial activation, and 
blood-brain barrier function.  
CSF ratios of NFL (A), NSE (B), VLP-1 (C), HFABP (D), YKL-40 (E), GFAP (F), MCP-1 
(G) and CSF/serum albumin ratio between AD and control groups. Individual AD/control 
ratios and their corresponding 95% CIs are indicated by filled squares. The size of the square 
indicates the weight of the study. All average ratios and their corresponding 95% CIs are 
indicated by clear diamonds. The solid line indicates a ratio of one and the dotted indicates the 
average ratio.  
 
Figure 4: AD/control ratios for CSF markers of APP metabolism.  
CSF ratios of Aβ40 (A), Aβ38 (B), sAPPα (C) and sAPPβ (D) between AD and control 
groups. Individual AD/control ratios and their corresponding 95% CIs are indicated by filled 
squares. The size of the square indicates the weight of the study. All average ratios and their 
corresponding 95% CIs are indicated by clear diamonds. The solid line indicates a ratio of one 
and the dotted indicates the average ratio.  
 
Figure 5: AD/control ratios for plasma biomarkers.  
Plasma or serum ratios of Aβ42 (A), Aβ40 (B), T-tau (C), NSE (D), HFABP (E), YKL-40  
(F), MCP-1 (G) between AD and control groups. Individual AD/control ratios and their 
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corresponding 95% CIs are indicated by filled squares. The size of the square indicates the 
weight of the study. All average ratios and their corresponding 95% CIs are indicated by clear 
diamonds. The solid line indicates a ratio of one and the dotted indicates the average ratio.  
 
Figure 6: MCI-AD/stable MCI ratios for CSF and plasma markers 
CSF ratios of T-tau (A), P-tau (B), Aβ42 (C), Aβ40 (D), sAPPα (G), sAPPβ (H) and plasma 
ratios of Aβ42 (E) and Aβ40 (F) between MCI-AD and stable MCI groups. Individual MCI-
AD/stable MCI ratios and their corresponding 95% CIs are indicated by filled squares. The 
size of the square indicates the weight of the study. All average ratios and their corresponding 
95% CIs are indicated by clear diamonds. The solid line indicates a ratio of one and the dotted 
indicates the average ratio.  
 
Figure 7: Biomarker performance rating in AD vs. controls. 
Head-to-head biomarker performance in CSF (Panel A) and in serum and plasma (Panel B) 
based on average AD/control ratios. The biomarkers in green circles were significant with 
good effect size and the ones in blue squares were significant with moderate effect size and 
the ones in red diamonds were non-significant or significant with minor effect size T-tau 2·54 
(95% CI 2·44-2·64, p<0·0001), NFL 2·35 (95% CI 1·90-2·91, p<0·0001), P-tau 1·88 (95% 
CI 1·79-1·97, p<0·0001), Aβ42 0·56 (95% CI 0·55-0·58, p<0·0001), NSE 1·47 (95% CI 
1·08-2·00, p=0·01), VLP-1 1·46 (95% CI 1·31-1·62, p<0·0001), HFABP 1·39 (95% CI 1·24-
1·57, p<0·0001), YKL-40 1·28 (95% CI 1·23-1·35, p<0·0001), MCP-1 1·12 (95% CI 1·06-
1·18, p<0·0001), GFAP 1·12 (95% CI 0·58-2·15, p=0·74), albumin ratio 1·10 (95% CI 1·01-
1·20, p=0·04), Aβ40 0·94 (95% CI 0·90-0·99, p=0·02), Aβ38 0·99 (95% CI 0·88-1·12, 
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p=0·89), sAPPα 1·03 (95% CI 0·93-1·14, p=0·55), and sAPPβ 1·02 (95% CI 0·95-1·09, 
p=0·61). Plasma and serum markers are depicted in black circles T-tau 1·95 (95% CI 1·12-
3·38, p=0·02), YKL-40 1·95 (95% CI 0·99-3·84, p=0·053), HFABP 1·05 (95% CI 0·83-1·33, 
p=0·69), Aβ40 1·04 (95% CI 0·98-1·11, p=0·17), Aβ42 1·04 (95% CI 0·96-1·12, p=0·32), 
MCP-1 1·00 (95% CI 0·89-1·13, p=0·99), and NSE 1·00 (95% CI 0·86-1·17, p=0·99). The 
AD/control ratios of CSF Aβ42, Aβ40, and Aβ38 were inverted to allow for a clearer 
comparison with the other biomarkers. The dotted line indicates a ratio of one. 
 
